Doxorubicin Hydrochloride, USP is an anthracycline antibiotic and 12-hydroxylated version of daunorubicin that inhibits macromolecular biosynthesis through DNA intercalation. This chemotherapeutic compound is used in cancer research for many different cancer types such as carcinomas, sarcomas, and hematological cancers.
Doxorubicin Hydrochloride, USP is soluble in water.
We also offer:
- Doxorubicin (D063)
| Mechanism of Action | Doxorubicin stops the development of the topoisomerase II enzyme, which relaxes supercoils in DNA for transcription. Doxorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, which prevents the DNA double helix from being resealed and thereby inhibits the replication process. |
| Impurity Profile | Impurity A| (8S,10S)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-l-lyxo-hexopyranosyl)oxy]-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione (daunorubicin)|||| Impurity B| (8S,10S)-10[(3-amino-2,3,6-trideoxy-l-lyxo-hexopyranosyl)oxy]-8-(2-bromo-1,1-dimethoxyethyl)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione|||| Impurity C| (8S,10S)-10[(3-amino-2,3,6-trideoxy-l-lyxo-hexopyranosyl)oxy]-8-(bromoacetyl)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione|||| Impurity D| (8S,10S)-6,8,10,11-tetrahydroxy-8-(hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione (doxorubicin aglycone, doxorubicinone)| |
| Cancer Applications | Doxorubicin is used for in vitro cancer research studies of non-Hodgkin's lymphoma, multiple myeloma, acute leukemias, Kaposi sarcoma, Ewing sarcoma and Wilm tumor. It is used in studies of cancer of the breast, adrenal cortex, endometrium, lung, ovary, and others. Advanced studies into the molecular mechanism of chemoresistance development would be beneficial to prevent cancer relapse (Sritharan and Sivalingam, 2021). |
| References |
Cristina C et al (2009) Doxorubicin: The good, the bad and the ugly effect. Current Med. Chem. 16(25):3267-3285 Sritharan S and Nageswaran Sivalingam N (2021) A comprehensive review on time-tested anticancer drug doxorubicin. Life Sciences 278:119527 Tacar O, Sriamornsak P, Dass CR (2013) Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol. 65(2):157–170 |
